Enveric Biosciences Inc. [NASDAQ: ENVB] stock went on a downward path that fall over -1.83% on Tuesday, amounting to a one-week price increase of more than 27.99%. The company report on March 16, 2021 that Diverse Biotech announces Strategic Transaction with Enveric Biosciences.
Diverse Biotech, Inc. www.diversebiotech.com announced that it has finalized a strategic transaction with Enveric Biosciences to license exclusive worldwide development and commercialization rights for five novel compounds to address the adverse side effects of cancer treatments. Diverse Biotech has created a highly advanced chemistry drug discovery platform that combines cannabinoids with other molecules to create new drug candidates with potentially greater efficacy and a more favorable side effect profile than standard therapy. Under the terms of the agreement, Diverse will receive an undisclosed up-front payment and royalties on sales of commercialized compounds in the territory.
“We are excited to collaborate with the outstanding leadership team at Enveric to take these important molecules from our novel conjugate chemistry platform into the supportive care indications of oncology. We believe that this relationship has the potential to advance this science more rapidly and efficiently, which ultimately better serves patients and allows us to focus on cancer treatment.” said Brian Longstreet, Interim CEO, Diverse Biotech. Brian adds “With potentially thousands of new chemical entities covered by our intellectual property patents, we believe this is just the beginning of future partnerships with companies looking to expand their drug portfolio.”.
Over the last 12 months, ENVB stock rose by 7.14%.
The market cap for the stock reached $64.65 million, with 18.34 million shares outstanding and 17.53 million shares in the current float. Compared to the average trading volume of 6.64M shares, ENVB stock reached a trading volume of 34776316 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Enveric Biosciences Inc. [ENVB]:
The Average True Range (ATR) for Enveric Biosciences Inc. is set at 0.77, with the Price to Sales ratio for ENVB stock in the period of the last 12 months amounting to 1.83. The Price to Book ratio for the last quarter was 1.51, with the Price to Cash per share for the same quarter was set at 0.16.
ENVB Stock Performance Analysis:
Enveric Biosciences Inc. [ENVB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 27.99. With this latest performance, ENVB shares dropped by -18.83% in over the last four-week period, additionally sinking by -15.54% over the last 6 months – not to mention a rise of 7.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ENVB stock in for the last two-week period is set at 49.35, with the RSI for the last a single of trading hit 51.64, and the three-weeks RSI is set at 48.12 for Enveric Biosciences Inc. [ENVB]. The present Moving Average for the last 50 days of trading for this stock 4.00, while it was recorded at 3.86 for the last single week of trading, and 5.65 for the last 200 days.
Insight into Enveric Biosciences Inc. Fundamentals:
Enveric Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.80.
Enveric Biosciences Inc. [ENVB] Insider Position Details
There are presently around $0 million, or 0.20% of ENVB stock, in the hands of institutional investors. The top three institutional holders of ENVB stocks are: VANGUARD GROUP INC with ownership of 12,183, which is approximately New of the company’s market cap and around 3.40% of the total institutional ownership; VIRTU FINANCIAL LLC, holding 10,514 shares of the stock with an approximate value of $39000.0 in ENVB stocks shares; and CITADEL ADVISORS LLC, currently with $38000.0 in ENVB stock with ownership of nearly New of the company’s market capitalization.
5 institutional holders increased their position in Enveric Biosciences Inc. [NASDAQ:ENVB] by around 32,905 shares. Additionally, 1 investors decreased positions by around 2,697 shares, while 1 investors held positions by with 1,692 shares. The mentioned changes placed institutional holdings at 33,910 shares, according to the latest SEC report filing. ENVB stock had 4 new institutional investments in for a total of 32,897 shares, while 1 institutional investors sold positions of 2,697 shares during the same period.